Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)
01:46pm, Monday, 27'th May 2024
Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HAE or BSX: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 27'th May 2024
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their b
Wall Street Analysts Believe Haemonetics (HAE) Could Rally 26.58%: Here's is How to Trade
10:56am, Friday, 24'th May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the pos
Haemonetics (HAE) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Thursday, 23'rd May 2024
Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes
06:00am, Thursday, 23'rd May 2024
BOSTON , May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Se
Here's Why You Should Buy Haemonetics (HAE) Stock Now
10:16am, Wednesday, 22'nd May 2024
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
Haemonetics Announces Proposed Convertible Senior Notes Offering
04:05pm, Tuesday, 21'st May 2024
BOSTON, May 21, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principa
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
01:01pm, Friday, 17'th May 2024
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
11:21am, Friday, 17'th May 2024
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
Haemonetics Corporation (HAE) Hit a 52 Week High, Can the Run Continue?
10:16am, Tuesday, 14'th May 2024
Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
10:46am, Monday, 13'th May 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand
11:56am, Friday, 10'th May 2024
Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.
Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript
12:25am, Friday, 10'th May 2024
Haemonetics Corporation (NYSE:HAE ) Q4 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Olga Guyette - Senior Director of Investor Relations and Treasury Christopher Simon - P
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
10:36am, Thursday, 09'th May 2024
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
08:21am, Thursday, 09'th May 2024
Haemonetics (HAE) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.77 per share a year ago.
